U.S. Markets close in 4 hrs 11 mins

Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019

SEATTLE--(BUSINESS WIRE)--

Omeros Corporation (OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018, on Friday, March 1, 2019, before the market opens. Omeros management will host a conference call and webcast that day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results.

Conference Call Details

To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The participant passcode is 3544038. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 3544038.

To access the live or subsequently archived webcast of the conference call on the internet, go to the company’s website at www.omeros.com and select “Events” under the Investors section of the website. To access the live webcast, please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Omeros Corporation

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The company’s drug product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is marketed for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. In the European Union, the European Commission has approved OMIDRIA for use in cataract surgery and other IOL replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, cognitive impairment and addictive and compulsive disorders. In addition, Omeros has a diverse group of preclinical programs and a proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and corresponding compounds, a number of which are in preclinical development. The company also exclusively possesses a novel antibody-generating platform.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190226005464/en/

  • Apple stock leads Dow higher after Morgan Stanley cites ‘attractive’ earnings setup
    Business
    MarketWatch

    Apple stock leads Dow higher after Morgan Stanley cites ‘attractive’ earnings setup

    Apple Inc. shares are rising in Monday trading after an analyst at Morgan Stanley praised the “attractive” setup heading into the company's earnings report next Tuesday. Morgan Stanley's Katy Huberty raised her price target on Apple's stock (AAPL)to $247 from $231, writing that the smartphone giant faces only a “low risk” of disappointing with its September outlook given a low bar on Wall Street. “Investor sentiment remains negative despite improving iPhone and services data points,” Huberty said in her note to clients.

  • Here's the next disaster in retail. Hint: it's not J.C. Penney dying
    Business
    Yahoo Finance

    Here's the next disaster in retail. Hint: it's not J.C. Penney dying

    Thanks to shoppers spending cautiously on clothes in recent months — despite a rallying stock market and low 3.7% unemployment rate — retailers of all kinds are sitting on mountains of excess inventory. Now that inventory must be worked off at profit-margin-busting prices in order to make way for the lucrative, full-price garb targeted to back to school shoppers in August and September. That backdrop sets the stage for scores of earnings misses, lowered profit outlooks and downtrodden earnings calls with Wall Street when the retail sector begins to release results in mid-August.

  • Business
    MarketWatch

    Tesla stock downgraded to hold at Roth Capital

    Analyst Craig Irwin at Roth Capital Partners on Monday downgraded Tesla Inc. (tsla) stock to their equivalent of hold, from buy, saying he sees the shares' risk-reward equation "as well balanced at current levels." Tesla has a "viable path tfor meeting at least the low end" of its guidance to deliver between 360,000 and 400,000 cars this year, he said. Tesla is scheduled to report second-quarter results on Wednesday. The stock is down 22% this year, contrasting with gains of 19% and 16% for the S&P 500 index (spx) and the Dow Jones Industrial Average.

  • Is Johnson & Johnson a Buy?
    Business
    Motley Fool

    Is Johnson & Johnson a Buy?

    All of this might make you think that Johnson & Johnson is a stock to avoid. But is it actually a smart pick for long-term investors to buy now? Here are the arguments for and against J&J. Reasons to buy One of the biggest attractions for Johnson & Johnson is its dividend.

  • Do the math. Here's why you shouldn't claim Social Security at 62
    News
    USA TODAY

    Do the math. Here's why you shouldn't claim Social Security at 62

    Many would-be beneficiaries use a break-even analysis which, in essence, tells them the age (or ages) when it makes the most financial sense to claim benefits. Using this sort of analysis can be helpful. But experts say it shouldn't be the only factor you consider when deciding when to apply for Social Security. You start the analysis by calculating what your cumulative benefits would be based on the age you apply for Social Security.

  • Israel Begins Demolishing Palestinian Homes in East Jerusalem
    World
    Meredith Videos

    Israel Begins Demolishing Palestinian Homes in East Jerusalem

    Israeli work crews on Monday began demolishing dozens of Palestinian homes in an east Jerusalem neighborhood, in one of the largest operations of its kind in years.

  • Micron stock rises after Goldman cheers shrinking inventories
    Business
    MarketWatch

    Micron stock rises after Goldman cheers shrinking inventories

    Memory companies appear to be depleting their NAND inventories more quickly than anticipated, and that's good news for Micron Technology Inc., according to Goldman Sachs. Analyst Mark Delaney upgraded Micron shares (MU) to buy from neutral on Monday, citing his expectations for an improved supply/demand balance in the coming months. The stock is up 2.8% in Monday morning trading.

  • What CyberArk Software Ltd.'s (NASDAQ:CYBR) ROE Can Tell Us
    Business
    Simply Wall St.

    What CyberArk Software Ltd.'s (NASDAQ:CYBR) ROE Can Tell Us

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. CyberArk Software has a ROE of 11%, based on the last twelve months. How Do I Calculate Return On Equity?

  • Should You Consider Allianz SE (FRA:ALV)?
    Business
    Simply Wall St.

    Should You Consider Allianz SE (FRA:ALV)?

    Attractive stocks have exceptional fundamentals. In the case of Allianz SE (FRA:ALV), there's is a well-regarded dividend payer that has been a rockstar for income investors, currently trading at an attractive share price. If you're interested in understanding beyond my broad commentary, read the full report on Allianz here.

  • Biogen, Celgene, Bristol-Myers and AbbVie report earnings this week: Here’s what to expect
    Business
    MarketWatch

    Biogen, Celgene, Bristol-Myers and AbbVie report earnings this week: Here’s what to expect

    Bristol-Myers, scheduled to announce second-quarter results on Thursday before the market opens, is expected to report earnings of $1.07 a share, up from $1.01 a share in the year-earlier quarter. Analysts polled by FactSet expect sales to rise to $6.109 billion from $5.704 billion a year ago, with the company's best-selling drug Eliquis expected to contribute $1.972 billion compared with $1.650 billion a year ago. Sales of Opdivo, another blockbuster drug, should rise to $1.815 billion from $1.627 billion a year ago.

  • What We Think Of Canadian Tire Corporation, Limited’s (TSE:CTC.A) Investment Potential
    Business
    Simply Wall St.

    What We Think Of Canadian Tire Corporation, Limited’s (TSE:CTC.A) Investment Potential

    Today we'll evaluate Canadian Tire Corporation, Limited (TSE:CTC.A) to determine whether it could have potential as an investment idea. In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. First up, we'll look at what ROCE is and how we calculate it.

  • Trump’s stock market still lags Obama’s, but that could be about to change
    Business
    MarketWatch

    Trump’s stock market still lags Obama’s, but that could be about to change

    Donald Trump loves telling us all about how fantastic the stock market has done under his leadership. McBride, for his part, says he doesn't believe the market is a great measure of policy performance, but he acknowledges that some, including Treasury Secretary Steven Mnuchin, do. “My view is there are many measures of success — and that the economy needs to work well for a majority of the people — not just stock investors,” McBride explained in a “just for fun” blog post over the weekend.

  • Business
    MarketWatch

    Applied Materials, Lam Research stocks rise after Goldman turns bullish

    Goldman Sachs analyst Toshiya Hari upgraded Applied Materials Inc. (amat) and Lam Research Corp. (lrcx) shares to buy from neutral on Monday, while also upgrading KLA Corp. shares (klac) to neutral from sell. Applied's shares have risen 46% so far this year, as the S&P 500 (spx) has gained 19%.

  • The Absurdity of Aurora Cannabis' Latest Analyst Downgrade
    Business
    Motley Fool

    The Absurdity of Aurora Cannabis' Latest Analyst Downgrade

    But Carey recently downgraded Aurora to neutral only three months after initiating coverage on the stock with a buy recommendation. Wall Street analysts change their views on stocks all of the time, of course. But this latest downgrade for Aurora illustrates the absurdity of giving too much weight to analysts' recommendations.

  • Vail Resorts set to acquire operator of 17 U.S. ski areas in $264M deal
    Business
    American City Business Journals

    Vail Resorts set to acquire operator of 17 U.S. ski areas in $264M deal

    Broomfield-based Vail Resorts Inc. NYSE: MTN) announced Monday morning that it is acquiring Peak Resorts Inc. Nasdaq: SKIS) in a deal valued at $264 million.

  • Wanna Bet $1.3 Trillion on Chinese Regulators?
    Business
    Bloomberg

    Wanna Bet $1.3 Trillion on Chinese Regulators?

    In fact, the country's largest search and e-commerce provider(1)is ultimately controlled by Alibaba Partnership, a collection of 38 people, most of whom hold senior positions in the company. This business structure, called a variable-interest entity, became common among Chinese companies because Beijing restricts foreign investment in certain sectors, such as the internet. It also enables firms to raise money abroad and lets early investors get their funds out of the country. Tencent Holdings Ltd., Meituan Dianping and Baidu Inc. all hew to various versions of the VIE, allowing them to exploit a gap in Chinese law.

  • Groups of Men in White Attack People in Hong Kong's Neighborhood of Yuen Long
    World
    Meredith Videos

    Groups of Men in White Attack People in Hong Kong's Neighborhood of Yuen Long

    In Hong Kong's Yuen Long, police were accused of responding too slowly as protesters came under attack by groups of men in white shirts with wooden sticks and other weapons on Sunday.

  • Where Will Sirius-XM Holdings Be in 5 Years?
    Business
    Motley Fool

    Where Will Sirius-XM Holdings Be in 5 Years?

    Satellite radio has never as popular as it is right now, but Sirius XM Holdings (NASDAQ: SIRI) investors aren't feeling the love. Growth is slowing, and it's fair for investors to question if satellite radio will be as ubiquitous in the future as it is today. Sirius XM has lived and died by its premium radio service that is consumed primarily by drivers.

  • Should We Worry About Broadcom Inc.'s (NASDAQ:AVGO) P/E Ratio?
    Business
    Simply Wall St.

    Should We Worry About Broadcom Inc.'s (NASDAQ:AVGO) P/E Ratio?

    A higher P/E ratio means that buyers have to pay a higher price for each $1 the company has earned over the last year. That isn't a good or a bad thing on its own, but a high P/E means that buyers have a higher opinion of the business's prospects, relative to stocks with a lower P/E. How Does Broadcom's P/E Ratio Compare To Its Peers? The P/E ratio indicates whether the market has higher or lower expectations of a company.

  • Amarin: Is a Buyout Really Off the Table?
    Business
    Motley Fool

    Amarin: Is a Buyout Really Off the Table?

    Amarin (NASDAQ: AMRN) drew the ire of its shareholders last week by rolling out a breathtaking $460 million capital raise. First up, the biopharma recently announced that sales of its prescription omega-3 treatment, Vascepa, have been going strong ever since the drug showed a 25% relative risk reduction in terms of serious cardiovascular events in the outcomes trial known as Reduce-It. Amarin, in turn, reported that its cash position stood at a healthy $221 million at the end of June, thanks to Vascepa's strong sales trajectory.

  • 2 Penny Stock Marijuana Plays That Could Make You Rich
    Business
    Motley Fool

    2 Penny Stock Marijuana Plays That Could Make You Rich

    That being said, there are some potential diamonds in the rough bumping around the penny cannabis stock landscape right now. For example, Aleafia Health (NASDAQOTH: ALEAF) and MedMen Enterprises (NASDAQOTH: MMNFF) both sport intriguing risk-to-reward ratios, despite their exceptionally low price per share. Here's a brief overview of the potential risks and rewards associated with these two penny pot stocks.

  • 1 Incredibly Cheap Pot Stock Worth Buying Now
    Business
    Motley Fool

    1 Incredibly Cheap Pot Stock Worth Buying Now

    The legalization of adult-use marijuana in Canada, the slow but steady march toward widespread legalization in the United States, and the 2018 Farm Bill -- that essentially legalized hemp -- all helped to drive valuations higher across the industry during this period. The industry's meteoric rise, though, has suddenly lost nearly all of its momentum over the past few weeks thanks to several weaker-than-expected earnings reports, mounting quarterly losses for almost every single publicly traded entity, more than a few abrupt leadership changes, the growing concern that the United States may not change marijuana's status as a Schedule I drug anytime soon, and a handful of high-profile scandals. Namely, there are a select few marijuana stocks that actually qualify as dyed-in-the-wool value plays following this turbulent period.

  • Business
    Market Realist

    Why Halliburton’s Q2 Earnings Rose Sequentially

    Halliburton (HAL) reported its second-quarter earnings on Monday before the markets opened. The company's earnings rose sequentially.

  • 7 Things You Didn't Know About NIO
    Business
    Motley Fool

    7 Things You Didn't Know About NIO

    Hitting the road Raising $1 billion during its initial public offering, NIO debuted as a publicly traded company on the American market in September 2018. According to Reuters, management had higher hopes for the IPO; a source close to the issue claimed that the company had sought a valuation as much as three times higher when it first began the IPO process. On its first day of trading, the stock opened at $6, closed at $6.60, and traded as high as $6.93 for a reasonable pop.

  • Should Investors Worry About J.C. Penney's Debt?
    Business
    Motley Fool

    Should Investors Worry About J.C. Penney's Debt?

    J.C. Penney's (NYSE: JCP) stock recently stumbled after Reuters claimed that the retailer "hired advisors to explore debt restructuring options." The report, which cited people "familiar with the matter," called the move a "high-stakes attempt to get its financial house in order" before its debt of nearly $4 billion matures within the next few years. J.C. Penney issued a press release to counter Reuters' report, stating that its liquidity was strong, that it had "no significant debt maturities coming due in the near term," and that it hadn't hired any advisors for an "in-court restructuring or bankruptcy."